Molecular Biology News and Research

RSS

Molecular biology is the study of biology at a molecular level. The field overlaps with other areas of biology and chemistry, particularly genetics and biochemistry. Molecular biology chiefly concerns itself with understanding the interactions between the various systems of a cell, including the interactions between DNA, RNA and protein biosynthesis as well as learning how these interactions are regulated.

AMP particpates at FDA's public meeting on oversight of laboratory developed tests

The Association for Molecular Pathology participated in the Food and Drug Administration Center for Devices and Radiological Health public meeting on the oversight of laboratory developed tests. Dr. Karen Mann, President of AMP, served on the second panel of the meeting titled, Clinical Laboratory Challenges. Additionally, Dr. Elaine Lyon, Chair of the AMP Professional Relations Committee, presented public comments. "AMP believes that LDTs are an essential and central component of medical practice," said Dr. Lyon, "Without LDTs, the practice of medicine that we know today would be severely reduced in scope."

21 Jul 2010

Major turning point in antiepileptic drug testing, development

New York University researchers revealed that data from previously completed withdrawal to monotherapy studies for antiepileptic drugs provide a valid control for future studies, obviating the need for placebo/pseudo-placebo trials to demonstrate the efficacy of these drugs as monotherapy. Results of this study are now available online in Epilepsia, a journal published by Wiley-Blackwell on behalf of the International League Against Epilepsy.

21 Jul 2010

Over-expression of Arpc1b promotes tumorigenic properties of breast cancer cells: Research

A major discovery, led by researchers from The George Washington University Medical Center, promises to revolutionize the way scientists think about key aspects of cellular lifecycle and offers a new avenue for cancer researchers to explore in their quest to one day slow down the progression of cancer.

21 Jul 2010

International Stem Cell, IBVI sign letter of intent concerning funding, establishment of ISCO India

International Stem Cell Corporation, www.internationalstemcell.com, and Insight Bioventures India Private Limited, announced today that they have signed a letter of intent concerning funding and establishment of an Indian affiliate of ISCO. The goal is to establish world-class development and manufacturing operations for ISCO's research and pharmaceutical products in India, including its Lifeline Cell Technology research products and human corneal tissue, CytoCor, for treatment of corneal vision impairment and testing of chemicals.

20 Jul 2010

Meridian Bioscience third-quarter net sales decrease 11% to $33.9 million

Net sales for the third quarter of fiscal 2010 were $33,857,000 as compared to $38,240,000 for the same period of the prior fiscal year, a decrease of 11%. Net earnings for the third quarter of fiscal 2010 were $6,424,000 or $0.16 per diluted share, both decreases of 24%, compared to the third quarter of fiscal 2009. (Net earnings include $673,000 in Bioline acquisition costs or $0.01 per diluted share.) Diluted common shares outstanding for fiscal 2010 and 2009 were 41,151,000 and 41,191,000, respectively.

20 Jul 2010

Meridian Bioscience completes acquisition of Bioline group of companies

Meridian Bioscience, Inc., Cincinnati, Ohio announces that effective today it will have completed the purchase of all the outstanding capital stock of the Bioline group of companies consisting of Bioline Ltd (UK), Bioline GmbH (Germany), Bioline (Aust) Pty Ltd (Australia), Bioline Reagents Ltd, and Bioline USA, Inc for $23.3 million in cash on hand.

20 Jul 2010

Bi-monthly journal on neurovirology from Springer

Starting in January 2011, Springer will publish the Journal of NeuroVirology, a bi-monthly publication closely affiliated with the International Society for NeuroVirology. Previously published by Taylor & Francis/Informa, the five-year contract with Springer runs to 2015.

20 Jul 2010

Corgenix, ELITech establish broad strategic alliance

Corgenix Medical Corporation, a worldwide developer and marketer of diagnostic test kits, and the ELITech Group, a Paris, France-based, privately held group of companies and worldwide manufacturer and distributor of in-vitro diagnostic equipment and reagents, today announced a broad strategic alliance.

19 Jul 2010

Microarrays acquired from Vanderbilt University

Microarrays, Inc. (MI), an innovator of array-based technologies for biological research, detection and diagnostics, today announced that the company's management team and a group of independent investors have purchased MI from Vanderbilt University. The new company structure will allow MI to more quickly and nimbly respond to client's rapidly expanding needs, especially within the diagnostic and health care arenas.

19 Jul 2010

GABA disrupts working memory in neurofibromatosis type 1 patients

Imagine if your brain lost its working memory - the ability to hold and manipulate information in your mind's eye. That's the plight faced by millions of people with neurofibromatosis type 1, or NF1. The genetic condition affects one in 3,500 people and is the most common cause of learning disabilities.Now a UCLA research team has uncovered new clues about how NF1 disrupts working memory. Published in the July 12 online edition of Proceedings of the National Academy of Sciences, the findings suggest a potential drug target for correcting NF1-related learning disabilities.

17 Jul 2010

Study on how cellular defence systems keep themselves in check from damaging cells themselves

When cells are attacked by bacteria they use all means at their disposal to defend themselves. But cellular defence systems can damage the cells themselves and so need to be kept tightly in check. Recent results help us to understand how this is done and give pointers to new ways of combating disease. Matthias Farlik in the group of Thomas Decker at the Centre for Molecular Biology of the University of Vienna (Max F. Perutz Laboratories) and Mathias Müller of the University of Veterinary Medicine, Vienna have published these findings in the current issue of the journal "Immunity".

16 Jul 2010

Studying retrovirus assembly can help new drug development for infection control

How a retrovirus, like HIV, reproduces and assembles new viruses is different than previously thought, according to Penn State College of Medicine researchers. Understanding the steps a virus takes for assembly could allow development of a way to prevent the spread of retroviral diseases. The team studied a chicken virus called Rous sarcoma virus that causes cancer in chickens and is similar to HIV.

16 Jul 2010

Spanish scientists develop new parasite detection method to prevent Anisakidosis

A new method enables anisakids to be detected in any fish product, from a whole fish, fresh or frozen, to tinned fish and surimi. Developed by Spanish scientists, the system is based on molecular techniques and overcomes the limitations of traditional procedures.

16 Jul 2010

NIH awards MacroGenics $9.8 million grant for three projects

MacroGenics, Inc, a privately held biotechnology company that develops immunotherapeutics to treat autoimmune disorders, cancer and infectious diseases, today announced that the National Institutes of Health (NIH) has awarded the company three new grants representing total funding of $9.8 million.

15 Jul 2010

Aduro BioTech announces issuance of two important patents

Aduro BioTech, a clinical-stage immunotherapy company, announced today the issuance of two important patents, the formation of a distinguished scientific advisory board, the addition of key members to its Board of Directors, and the reporting of preliminary top line long-term survival data from a Phase 1 clinical trial with 2 year follow-up.

15 Jul 2010

Maven Semantic releases updates to Biotechnology research database

Maven Semantic (http://www.mavensemantic.com) announces updates to their Biotechnology research database.

14 Jul 2010

ZyGEM launches new microbial fingerprinting diagnostic technology

ZyGEM Corp. Ltd., has introduced its new microbial fingerprinting diagnostic technology that is expected to dramatically reduce the complexity and time needed to identify unknown infectious agents in mixed population samples. The approach is designed to run on the company's new MicroLab platform and has the potential to accurately identify up to 30 types of microbes simultaneously from a single sample in less than an hour.

14 Jul 2010